| Year |
Citation |
Score |
| 2023 |
Kfoury YS, Ji F, Jain E, Mazzola MC, Schiroli G, Papazian A, Mercier FE, Sykes DB, Kiem A, Randolph MA, Abdel-Wahab OI, Calvi LM, Sadreyev R, Scadden DT. The bone marrow stroma in human myelodysplastic syndrome reveals alterations that regulate disease progression. Blood Advances. PMID 37450380 DOI: 10.1182/bloodadvances.2022008268 |
0.315 |
|
| 2023 |
Rhee C, Scadden EW, Wong LP, Schiroli G, Mazzola MC, Chea PL, Kato H, Hoyer FF, Mistry M, Lee BK, Kim J, Nahrendorf M, Mansour M, Sykes DB, Sadreyev R, et al. Limited plasticity of monocyte fate and function associated with epigenetic scripting at the level of progenitors. Blood. PMID 37267513 DOI: 10.1182/blood.2023020257 |
0.311 |
|
| 2022 |
Wang H, He X, Zhang L, Dong H, Huang F, Xian J, Li M, Chen W, Lu X, Pathak KV, Huang W, Li Z, Zhang L, Nguyen LXT, Yang L, ... ... Sykes DB, et al. Disruption of dNTPs Homeostasis by Ribonucleotide Reductase Hyperactivation Overcomes AML Differentiation Blockade. Blood. PMID 35439288 DOI: 10.1182/blood.2021015108 |
0.3 |
|
| 2021 |
Blanco MA, Sykes DB, Gu L, Wu M, Petroni R, Karnik R, Wawer M, Rico J, Li H, Jacobus WD, Jambhekar A, Cheloufi S, Meissner A, Hochedlinger K, Scadden DT, et al. Chromatin-state barriers enforce an irreversible mammalian cell fate decision. Cell Reports. 37: 109967. PMID 34758323 DOI: 10.1016/j.celrep.2021.109967 |
0.303 |
|
| 2020 |
van Gastel N, Spinelli JB, Sharda A, Schajnovitz A, Baryawno N, Rhee C, Oki T, Grace E, Soled HJ, Milosevic J, Sykes DB, Hsu PP, Vander Heiden MG, Vidoudez C, Trauger SA, et al. Induction of a Timed Metabolic Collapse to Overcome Cancer Chemoresistance. Cell Metabolism. PMID 32763164 DOI: 10.1016/J.Cmet.2020.07.009 |
0.365 |
|
| 2020 |
Yusuf R, Saez B, Sharda A, van Gastel N, Yu V, Baryawno N, Scadden EW, Acharya SS, Chattophadhyay S, Huang C, Viswanathan V, S'aulis D, Cobert J, Sykes DB, Keibler MA, et al. Aldehyde dehydrogenase 3a2 protects AML cells from oxidative death and the synthetic lethality of ferroptosis inducers. Blood. PMID 32458004 DOI: 10.1182/Blood.2019001808 |
0.358 |
|
| 2020 |
Negoro PE, Xu S, Dagher Z, Hopke A, Reedy JL, Feldman MB, Khan NS, Viens AL, Alexander NJ, Atallah NJ, Scherer AK, Dutko RA, Jeffery J, Kernien JF, Fites JS, ... ... Sykes DB, et al. Spleen Tyrosine Kinase Is a Critical Regulator of Neutrophil Responses to Species. Mbio. 11. PMID 32398316 DOI: 10.1128/Mbio.02043-19 |
0.376 |
|
| 2020 |
Nguyen GT, Shaban L, Mack M, Swanson KD, Bunnell SC, Sykes DB, Mecsas J. SKAP2 is required for defense against infection and neutrophil respiratory burst. Elife. 9. PMID 32352382 DOI: 10.7554/Elife.56656 |
0.309 |
|
| 2020 |
Cabal-Hierro L, van Galen P, Prado MA, Higby KJ, Togami K, Mowery CT, Paulo JA, Xie Y, Cejas P, Furusawa T, Bustin M, Long HW, Sykes DB, Gygi SP, Finley D, et al. Chromatin accessibility promotes hematopoietic and leukemia stem cell activity. Nature Communications. 11: 1406. PMID 32179749 DOI: 10.1038/S41467-020-15221-Z |
0.407 |
|
| 2020 |
Lee S, Micalizzi D, Truesdell SS, Bukhari SIA, Boukhali M, Lombardi-Story J, Kato Y, Choo MK, Dey-Guha I, Ji F, Nicholson BT, Myers DT, Lee D, Mazzola MA, Raheja R, ... ... Sykes D, et al. A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cells. Genome Biology. 21: 33. PMID 32039742 DOI: 10.1186/S13059-020-1936-4 |
0.354 |
|
| 2019 |
Christian S, Merz C, Evans L, Gradl S, Seidel H, Friberg A, Eheim A, Lejeune P, Brzezinka K, Zimmermann K, Ferrara S, Meyer H, Lesche R, Stoeckigt D, Bauser M, ... ... Sykes DB, et al. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia. PMID 30940908 DOI: 10.1038/S41375-019-0461-5 |
0.382 |
|
| 2019 |
Kugadas A, Geddes-McAlister J, Guy E, DiGiandomenico A, Sykes DB, Mansour MK, Mirchev R, Gadjeva M. Frontline Science: Employing enzymatic treatment options for management of ocular biofilm-based infections. Journal of Leukocyte Biology. PMID 30690787 DOI: 10.1002/Jlb.4Hi0918-364Rr |
0.304 |
|
| 2019 |
Sexauer AN, Do B, Sykes DB. Loss of FLT3 Sensitizes Myeloid Cells to Differentiation Via DHODH Inhibition Blood. 134: 2712-2712. DOI: 10.1182/Blood-2019-128910 |
0.443 |
|
| 2019 |
Kfoury Y, Ji F, Mazzola M, Sykes DB, Anthony A, Akiyama Y, Scherer A, Mercier F, Severe N, Saez B, Seidl J, Papazian A, Brouse T, Mansour MK, Ivanov P, et al. Niche Transfer of Small Non-Coding RNAs Regulates Hematopoietic Response to Stress Blood. 134: 1207-1207. DOI: 10.1182/Blood-2019-124794 |
0.391 |
|
| 2019 |
Rhee CS, Scadden EW, Phillip CL, Lee B, Mistry M, Hoyer FF, Kato H, Mantica G, Kim J, Nahrendorf M, Mansour MK, Sykes DB, Scadden DT. Functionally Distinct Subsets of Monocytes in Mouse and Human Blood Blood. 134: 438-438. DOI: 10.1182/Blood-2019-124054 |
0.441 |
|
| 2019 |
Eheim A, Christian S, Meyer H, Stoeckigt D, Merz C, Zimmermann K, Bauser M, Haegebarth A, Ferrara S, Sykes DB, Scadden DT, Gradl S, Janzer A. Abstract 3597: BAY 2402234: Preclinical evaluation of a novel, selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of diffuse large B-cell lymphoma (DLBCL) Cancer Research. 79: 3597-3597. DOI: 10.1158/1538-7445.Am2019-3597 |
0.364 |
|
| 2019 |
Gradl SN, Mueller T, Ferrara S, Sheikh SE, Janzer A, Zhou H, Friberg A, Guenther J, Schaefer M, Stellfeld T, Eis K, Kroeber M, Nguyen D, Merz C, Niehues M, ... ... Sykes DB, et al. Abstract 2: Discovery of BAY 2402234 by phenotypic screening: A human Dihydroorotate Dehydrogenase (DHODH) inhibitor in clinical trials for the treatment of myeloid malignancies Cancer Research. 79: 2-2. DOI: 10.1158/1538-7445.Am2019-2 |
0.307 |
|
| 2018 |
Lin B, Srikanth P, Castle AC, Nigwekar S, Malhotra R, Galloway JL, Sykes DB, Rajagopal J. Modulating Cell Fate as a Therapeutic Strategy. Cell Stem Cell. PMID 29910150 DOI: 10.1016/J.Stem.2018.05.009 |
0.348 |
|
| 2018 |
Sykes DB, Schroyens W. Complete Responses in the TEMPI Syndrome after Treatment with Daratumumab. The New England Journal of Medicine. 378: 2240-2242. PMID 29874534 DOI: 10.1056/Nejmc1804415 |
0.317 |
|
| 2018 |
Dagher Z, Xu S, Negoro PE, Khan NS, Feldman MB, Reedy JL, Tam JM, Sykes DB, Mansour MK. Fluorescent Tracking of Yeast Division Clarifies the Essential Role of Spleen Tyrosine Kinase in the Intracellular Control of in Macrophages. Frontiers in Immunology. 9: 1058. PMID 29868018 DOI: 10.3389/Fimmu.2018.01058 |
0.334 |
|
| 2018 |
Fites JS, Gui M, Kernien JF, Negoro P, Dagher Z, Sykes DB, Nett JE, Mansour MK, Klein BS. An unappreciated role for neutrophil-DC hybrids in immunity to invasive fungal infections. Plos Pathogens. 14: e1007073. PMID 29782541 DOI: 10.1371/Journal.Ppat.1007073 |
0.339 |
|
| 2018 |
Kfoury Y, Jain E, Myers JR, Ji F, Sykes DB, Mercier F, Papazian A, Le C, Randolph MA, Steensma DP, Abdel-Wahab OI, Calvi LM, Sadreyev RI, Becker MW, Scadden DT. Specific Bone Marrow Mesenchymal Subsets in Patients with Myelodysplastic Syndromes Harbor Molecular Perturbations That Alter the Dynamics of Competition between Pre-Leukemic Clones and Normal Cells Blood. 132: 938-938. DOI: 10.1182/Blood-2018-99-115242 |
0.369 |
|
| 2018 |
Hsu PP, Kfoury Y, Aziz N, Elkhoury J, Hallgren B, Scadden DT, Vander Heiden M, Sykes DB. DHODH Inhibitors in the Treatment of Acute Myeloid Leukemia: Defining the Mechanism of Action and the Basis of the Metabolic Therapeutic Window Blood. 132: 2716-2716. DOI: 10.1182/Blood-2018-99-113387 |
0.412 |
|
| 2018 |
Janzer A, Gradl S, Christian S, Zimmermann K, Merz C, Meyer H, Stellfeld T, Guenther J, Stoeckigt D, Seidel H, Lejeune P, Bruening M, Eheim A, Mueller T, Lesche R, ... ... Sykes D, et al. Abstract DDT02-04: BAY 2402234: A novel, selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of myeloid malignancies Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ddt02-04 |
0.399 |
|
| 2018 |
Mercier F, Shi J, Sykes D, Oki T, Miller E, Vasic R, Zhu A, Severe N, Schajnovitz A, Man C, Kfoury Y, Lee D, Doench J, Hide W, Michor F, et al. In Vivo Profiling of Leukemic Stem Cell Fitness Identifies Therapeutically Actionable Determinants of Growth Experimental Hematology. 64: S86. DOI: 10.1016/J.Exphem.2018.06.095 |
0.356 |
|
| 2017 |
Lee PY, Sykes DB, Ameri S, Kalaitzidis D, Charles JF, Nelson-Maney N, Wei K, Cunin P, Morris A, Cardona AE, Root DE, Scadden DT, Nigrovic PA. The metabolic regulator mTORC1 controls terminal myeloid differentiation. Science Immunology. 2. PMID 28763796 DOI: 10.1126/Sciimmunol.Aam6641 |
0.453 |
|
| 2017 |
Kalaitzidis D, Lee D, Efeyan A, Kfoury Y, Nayyar N, Sykes DB, Mercier FE, Papazian A, Baryawno N, Victora GD, Neuberg D, Sabatini DM, Scadden DT. Amino acid-insensitive mTORC1 regulation enables nutritional stress resilience in hematopoietic stem cells. The Journal of Clinical Investigation. PMID 28319048 DOI: 10.1172/Jci89452 |
0.394 |
|
| 2017 |
Mercier F, Shi J, Sykes DB, Miller E, Oki T, Man C, Yan X, Kfoury Y, Lee D, Doench JG, Michor F, Scadden DT. A Genome-Wide, In Vivo, Dropout CRISPR Screen in Acute Myeloid Leukemia Identifies an Essential Role for Beta-Galactosylation in Leukemic Cell Homing Blood. 130: 2493-2493. DOI: 10.1182/Blood.V130.Suppl_1.2493.2493 |
0.41 |
|
| 2017 |
Janzer A, Sykes D, Gradl S, Ferrara S, Christian S, Merz C, Seidel H, Bernthaler A, Lesche R, Wawer M, Scadden DT. Abstract 3086: Inhibitors of the enzyme dihydroorotate dehydrogenase, overcome the differentiation blockade in acute myeloid leukemia Cancer Research. 77: 3086-3086. DOI: 10.1158/1538-7445.Am2017-3086 |
0.413 |
|
| 2016 |
Lewis TA, Sykes DB, Law JM, Muñoz B, Rustiguel JK, Nonato MC, Scadden DT, Schreiber SL. Development of ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid Leukemia. Acs Medicinal Chemistry Letters. 7: 1112-1117. PMID 27994748 DOI: 10.1021/Acsmedchemlett.6B00316 |
0.401 |
|
| 2016 |
Hahm E, Wei C, Fernandez I, Li J, Tardi NJ, Tracy M, Wadhwani S, Cao Y, Peev V, Zloza A, Lusciks J, Hayek SS, O'Connor C, Bitzer M, Gupta V, ... ... Sykes DB, et al. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. Nature Medicine. PMID 27941791 DOI: 10.1038/Nm.4242 |
0.331 |
|
| 2016 |
Sykes DB, Kfoury YS, Mercier FE, Wawer MJ, Law JM, Haynes MK, Lewis TA, Schajnovitz A, Jain E, Lee D, Meyer H, Pierce KA, Tolliday NJ, Waller A, Ferrara SJ, et al. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell. PMID 27641501 DOI: 10.1016/J.Cell.2016.08.057 |
0.442 |
|
| 2016 |
Palchaudhuri R, Saez B, Hoggatt J, Schajnovitz A, Sykes DB, Tate TA, Czechowicz A, Kfoury Y, Ruchika F, Rossi DJ, Verdine GL, Mansour MK, Scadden DT. Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nature Biotechnology. PMID 27272386 DOI: 10.1038/Nbt.3584 |
0.372 |
|
| 2016 |
Mercier FE, Sykes DB, Scadden DT. Single Targeted Exon Mutation Creates a True Congenic Mouse for Competitive Hematopoietic Stem Cell Transplantation: The C57BL/6-CD45.1(STEM) Mouse. Stem Cell Reports. PMID 27185283 DOI: 10.1016/J.Stemcr.2016.04.010 |
0.314 |
|
| 2016 |
Lee D, Wang YH, Kalaitzidis D, Ramachandran J, Eda H, Sykes DB, Raje N, Scadden DT. Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy. The Journal of Clinical Investigation. PMID 26927669 DOI: 10.1172/Jci84620 |
0.353 |
|
| 2016 |
Sykes DB, Kfoury YS, Mercier F, Wawer M, Schajnovitz A, Meyer H, Pierce KA, Stoeckigt D, Clish CB, Clemons PA, Janzer A, Scadden DT. Inhibition of the Enzyme Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia Blood. 128: 1656-1656. DOI: 10.1182/Blood.V128.22.1656.1656 |
0.442 |
|
| 2015 |
Chen E, Ahn JS, Sykes DB, Breyfogle LJ, Godfrey AL, Nangalia J, Ko A, DeAngelo DJ, Green AR, Mullally A. RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. Cell Reports. 13: 2345-52. PMID 26686625 DOI: 10.1016/J.Celrep.2015.11.037 |
0.306 |
|
| 2015 |
Kenderian SS, Rosado FG, Sykes DB, Hoyer JD, Lacy MQ. Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation. Leukemia. PMID 26500143 DOI: 10.1038/Leu.2015.298 |
0.315 |
|
| 2015 |
Yoon KW, Byun S, Kwon E, Hwang SY, Chu K, Hiraki M, Jo SH, Weins A, Hakroush S, Cebulla A, Sykes DB, Greka A, Mundel P, Fisher DE, Mandinova A, et al. Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science (New York, N.Y.). 349. PMID 26228159 DOI: 10.1126/Science.1261669 |
0.355 |
|
| 2015 |
Belizaire R, Sykes DB, Chen YB, Spitzer TR, Makar RS. Difficulties in hematopoietic progenitor cell collection from a patient with TEMPI syndrome and severe iatrogenic iron deficiency. Transfusion. PMID 25911963 DOI: 10.1111/Trf.13125 |
0.355 |
|
| 2015 |
Chattopadhyay S, Stewart AL, Mukherjee S, Huang C, Hartwell KA, Miller PG, Subramanian R, Carmody LC, Yusuf RZ, Sykes DB, Paulk J, Vetere A, Vallet S, Santo L, Cirstea DD, et al. Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. Cell Reports. PMID 25660025 DOI: 10.1016/J.Celrep.2015.01.017 |
0.36 |
|
| 2015 |
Rosado FG, Oliveira JL, Sohani AR, Schroyens W, Sykes DB, Kenderian SS, Lacy MQ, Kyle RA, Hoyer JD. Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 28: 367-72. PMID 25216227 DOI: 10.1038/Modpathol.2014.117 |
0.335 |
|
| 2015 |
Perez-Ladaga A, Xie H, Orkin SH, Sykes DB, Ebert BL, Bejar R. Neutrophils Derived from Ezh2 -/- Progenitor Cells Demonstrate Aberrant Erythroid Lineage Gene Expression Blood. 126: 4112-4112. DOI: 10.1182/Blood.V126.23.4112.4112 |
0.444 |
|
| 2015 |
Palchaudhuri R, Saez B, Hoggatt J, Schajnovitz A, Sykes DB, Mansour MK, Scadden DT. Immunotoxin Enables Non-Genotoxic Conditioning for Hematopoietic Stem Cell Transplantation Blood. 126: 32-32. DOI: 10.1182/Blood.V126.23.32.32 |
0.332 |
|
| 2014 |
Mercier F, Shi J, Sykes D, Kfoury YS, Yusuf RZ, Miller E, Vasic R, Zhu A, Michor F, Hide W, Scadden DT. Identification of a Gene Expression Signature Characterizing Clonal Fitness and Dominance in Vivo in a Murine Model of MLL-AF9 Leukemia Blood. 124: 2383-2383. DOI: 10.1182/Blood.V124.21.2383.2383 |
0.42 |
|
| 2014 |
Sykes D, Kfoury Y, Blanco A, Scadden D. Phenotypic screening identifies prostacyclin agonists as differentiation agents in the treatment of acute myeloid leukemia Experimental Hematology. 42: S25. DOI: 10.1016/J.Exphem.2014.07.085 |
0.463 |
|
| 2013 |
Simic P, Zainabadi K, Bell E, Sykes DB, Saez B, Lotinun S, Baron R, Scadden D, Schipani E, Guarente L. SIRT1 regulates differentiation of mesenchymal stem cells by deacetylating β-catenin. Embo Molecular Medicine. 5: 430-40. PMID 23364955 DOI: 10.1002/Emmm.201201606 |
0.391 |
|
| 2013 |
Palchaudhuri R, Ang K, Saez B, Sykes DB, Verdine GL, Scadden DT. Differentiation Induction In Acute Myeloid Leukemia Using Site-Specific DNA-Targeting Blood. 122: 3940-3940. DOI: 10.1182/Blood.V122.21.3940.3940 |
0.409 |
|
| 2013 |
Geng H, Hurtz C, Chen Z, Chen W, Ballabio E, Xiao G, Kweon S, Nahar R, Sojaee S, Chan LN, Masouleh BK, Sykes DB, Melnick A, Roeder R, Milne T, et al. Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia Blood. 122: 349-349. DOI: 10.1182/Blood.V122.21.349.349 |
0.376 |
|
| 2013 |
Perez-Ladaga A, Caughey B, Xie H, Orkin SH, Sykes DB, Ebert BL, Bejar R. Functional Defects In Neutrophils Derived From Ezh2 Null Mice Blood. 122: 1556-1556. DOI: 10.1182/Blood.V122.21.1556.1556 |
0.44 |
|
| 2013 |
Simic P, Zainabadi K, Bell E, Sykes DB, Saez B, Lotinun S, Baron R, Scadden D, Schipani E, Guarente L. Corrigendum to SIRT1 regulates differentiation of mesenchymal stem cells by deacetylating β-catenin [EMBO Mol Med] DOI:10.1002/emmm.201201606 Embo Molecular Medicine. 5: 482. DOI: 10.1002/Emmm.201390004 |
0.351 |
|
| 2012 |
Park D, Sykes DB, Scadden DT. The hematopoietic stem cell niche. Frontiers in Bioscience (Landmark Edition). 17: 30-9. PMID 22201730 DOI: 10.2741/3913 |
0.389 |
|
| 2012 |
Schroyens WA, O'Connell CL, Lacy MQ, Attar EC, Raje N, Somer BG, Rosado FG, Hoyer J, Feinstein DI, Sykes DB. TEMPI: A Reversible Syndrome Following Treatment with Bortezomib Blood. 120: 986-986. DOI: 10.1182/Blood.V120.21.986.986 |
0.32 |
|
| 2012 |
Chattopadhyay S, Stewart AL, Mukherjee S, Huang C, Hartwell KA, Miller PG, Carmody L, Yusuf RZ, Sykes DB, Vallet S, Santo L, Cirstea DD, Hideshima T, Dancik V, Cheah J, et al. Niche-Based Screening Identifies Novel Small Molecules That Overcome Stromal Effects in Multiple Myeloma Blood. 120: 571-571. DOI: 10.1182/Blood.V120.21.571.571 |
0.37 |
|
| 2012 |
Sykes DB, Haynes MK, Tolliday N, Waller A, Cobert JM, Szekely BA, Hasaka TP, Sklar L, Zon LI, Scadden DT. Identifying Small Molecules That Overcome HoxA9-Mediated Differentiation Arrest in Acute Myeloid Leukemia Blood. 120: 3513-3513. DOI: 10.1182/Blood.V120.21.3513.3513 |
0.482 |
|
| 2012 |
Yusuf RZ, Acharya SS, Yu VW, Saez B, Cobert JM, Doench J, Bullinger L, S'aulis D, Lee D, Palchaudhuri R, Uzosike AC, Duvet M, Logan DJ, Das S, Cook CM, ... ... Sykes DB, et al. Aldehyde Dehydrogenase 3a2 (Aldh3a2) Represents a Distinct Metabolic Vulnerability in MLL-AF9 AML Leukemia Initiating Cells Blood. 120: 208-208. DOI: 10.1182/Blood.V120.21.208.208 |
0.414 |
|
| 2011 |
Sykes DB, Schroyens WA, O'Connell CL, Feinstein DI, Bazari H, Dahl DM, Colvin RB, Paelinck BP, Uppot RN, Beeck BOd, Boswell W, Raje NS, Harris NL, Attar EC. The TEMPI Syndrome: Telangiectasias, Elevated Erythropoietin and Erythrocytosis, Monoclonal Gammopathy, Perinephric Fluid Collections, and Intrapulmonary Shunting Blood. 118: 1037-1037. DOI: 10.1182/Blood.V118.21.1037.1037 |
0.317 |
|
| 2009 |
Scheele JS, Kolanczyk M, Gantert M, Zemojtel T, Dorn A, Sykes DB, Sykes DP, Möbest DC, Kamps MP, Räpple D, Duchniewicz M. The Spt-Ada-Gcn5-acetyltransferase complex interaction motif of E2a is essential for a subset of transcriptional and oncogenic properties of E2a-Pbx1. Leukemia & Lymphoma. 50: 816-28. PMID 19399691 DOI: 10.1080/10428190902836107 |
0.618 |
|
| 2007 |
Odegaard JI, Vats D, Zhang L, Ricardo-Gonzalez R, Smith KL, Sykes DB, Kamps MP, Chawla A. Quantitative expansion of ES cell-derived myeloid progenitors capable of differentiating into macrophages. Journal of Leukocyte Biology. 81: 711-9. PMID 17158607 DOI: 10.1189/Jlb.0906590 |
0.669 |
|
| 2006 |
Wang GG, Calvo KR, Pasillas MP, Sykes DB, Häcker H, Kamps MP. Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. Nature Methods. 3: 287-93. PMID 16554834 DOI: 10.1038/Nmeth865 |
0.743 |
|
| 2004 |
Sykes DB, Kamps MP. E2a/Pbx1 induces the rapid proliferation of stem cell factor-dependent murine pro-T cells that cause acute T-lymphoid or myeloid leukemias in mice. Molecular and Cellular Biology. 24: 1256-69. PMID 14729970 DOI: 10.1128/Mcb.24.3.1256-1269.2004 |
0.628 |
|
| 2003 |
Sykes DB, Scheele J, Pasillas M, Kamps MP. Transcriptional profiling during the early differentiation of granulocyte and monocyte progenitors controlled by conditional versions of the E2a-Pbx1 oncoprotein. Leukemia & Lymphoma. 44: 1187-99. PMID 12916872 DOI: 10.1080/1042819031000090273 |
0.66 |
|
| 2003 |
Sykes DB, Kamps MP. Estrogen-regulated conditional oncoproteins: tools to address open questions in normal myeloid cell function, normal myeloid differentiation, and the genetic basis of differentiation arrest in myeloid leukemia. Leukemia & Lymphoma. 44: 1131-9. PMID 12916864 DOI: 10.1080/1042819031000063444 |
0.682 |
|
| 2002 |
Welch JS, Escoubet-Lozach L, Sykes DB, Liddiard K, Greaves DR, Glass CK. TH2 cytokines and allergic challenge induce Ym1 expression in macrophages by a STAT6-dependent mechanism. The Journal of Biological Chemistry. 277: 42821-9. PMID 12215441 DOI: 10.1074/Jbc.M205873200 |
0.384 |
|
| 2002 |
Calvo KR, Sykes DB, Pasillas MP, Kamps MP. Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1. Oncogene. 21: 4247-56. PMID 12082612 DOI: 10.1038/Sj.Onc.1205516 |
0.734 |
|
| 2002 |
Klappacher GW, Lunyak VV, Sykes DB, Sawka-Verhelle D, Sage J, Brard G, Ngo SD, Gangadharan D, Jacks T, Kamps MP, Rose DW, Rosenfeld MG, Glass CK. An induced Ets repressor complex regulates growth arrest during terminal macrophage differentiation. Cell. 109: 169-80. PMID 12007404 DOI: 10.1016/S0092-8674(02)00714-6 |
0.644 |
|
| 2001 |
Calvo KR, Knoepfler PS, Sykes DB, Pasillas MP, Kamps MP. Meis1a suppresses differentiation by G-CSF and promotes proliferation by SCF: potential mechanisms of cooperativity with Hoxa9 in myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 98: 13120-5. PMID 11687616 DOI: 10.1073/Pnas.231115398 |
0.733 |
|
| 2001 |
Sykes DB, Kamps MP. Estrogen-dependent E2a/Pbx1 myeloid cell lines exhibit conditional differentiation that can be arrested by other leukemic oncoproteins. Blood. 98: 2308-18. PMID 11588024 DOI: 10.1182/Blood.V98.8.2308 |
0.682 |
|
| 2001 |
Knoepfler PS, Sykes DB, Pasillas M, Kamps MP. HoxB8 requires its Pbx-interaction motif to block differentiation of primary myeloid progenitors and of most cell line models of myeloid differentiation. Oncogene. 20: 5440-8. PMID 11571641 DOI: 10.1038/Sj.Onc.1204710 |
0.669 |
|
| 2000 |
Calvo KR, Sykes DB, Pasillas M, Kamps MP. Hoxa9 immortalizes a granulocyte-macrophage colony-stimulating factor-dependent promyelocyte capable of biphenotypic differentiation to neutrophils or macrophages, independent of enforced meis expression. Molecular and Cellular Biology. 20: 3274-85. PMID 10757811 DOI: 10.1128/Mcb.20.9.3274-3285.2000 |
0.727 |
|
| 1997 |
Parney IF, Petruk KC, Zhang C, Farr-Jones M, Sykes DB, Chang LJ. Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model. Human Gene Therapy. 8: 1073-85. PMID 9189765 DOI: 10.1089/Hum.1997.8.9-1073 |
0.352 |
|
| Show low-probability matches. |